Recombinant Virus Purification
Recombinant Virus Purification - Related Videos
04:12
Production and Purification of Recombinant Hepatitis B Virus Particles
0 Views •
2026
Source: Nishitsuji, H., et al. Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle. J. Vis. Exp. (2017)This video demonstrates the production and purification of recombinant Hepatitis B virus particles, enabling safe, replication-deficient viral preparations for studying early infection events and for high-throughput antiviral drug screening applications.
07:50
Detection and Removal of Nuclease Contamination During Purification of Recombinant Prototype Foamy Virus Integrase
0 Views •
Cited by 10 •
2017
Recombinant prototype foamy virus integrase protein is often contaminated with a bacterial nuclease during purification. This method identifies nuclease contamination and removes it from the final preparation of the enzyme.
03:33
Fluorescence-Based Detection and Purification of Recombinant Vaccinia Virus
0 Views •
2026
Source: Yuan, M., et al. A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors. J. Vis. Exp. (2016)This video demonstrates the process of performing a fluorescent plaque assay using recombinant vaccinia virus encoding red fluorescent protein (RFP) in fibroblast cells, followed by plaque isolation and purification for further analysis.
05:56
Purification of Recombinant Virus Particles from Transfected Human Kidney Cells
0 Views •
2026
Source: Ding, J. et. al., Preparation of rAAV9 to Overexpress or Knockdown Genes in Mouse Hearts. J. Vis. Exp. (2016)This video shows the purification of recombinant virus particles from transfected human kidney cells. The virus is released by freeze–thaw lysis and purified using iodixanol gradients with block copolymer-assisted filtration.
11:31
Generation of Recombinant Influenza Virus from Plasmid DNA
0 Views •
Cited by 129 •
2010
Rescue of influenza A viruses from plasmid DNA is a basic and essential experimental technique that allows influenza researchers to generate recombinant viruses to study multiple aspects in the biology of influenza virus, and to be used as potential vectors or vaccines.
FAQs
Clarification reduces the burden of host-cell debris before selective purification is applied. In a recombinant virus purification workflow, this step is paired with concentration and purification rather than treated as a complete solution, because the preparation may still contain empty or incomplete particles, residual nucleic acids, and other contaminants. Its value is creating a cleaner input for later separation.
The separation strategy can exploit differences in particle size, density, surface properties, or binding behavior. These distinctions allow filtration, centrifugation, or chromatography to treat viral particles and unwanted material differently. The most useful property depends on the composition of the preparation, including whether the main concern is host-cell debris, incomplete particles, residual nucleic acids, or another contaminant.
Filtration separates material according to size-related behavior, whereas centrifugation uses differences in density. Chromatography relies on how particles or contaminants interact with a surface or binding medium. Because these methods use different physical or surface properties, recombinant virus purification commonly combines clarification with selective concentration and purification rather than depending on one separation principle alone.
A preparation can be physically purified yet unsuitable if its desired biological activity is reduced. Preserving infectivity or another relevant activity ensures that the recovered recombinant virus remains useful for gene-delivery studies, vaccine development, or functional assays. This requirement influences how purification steps are selected and evaluated, alongside particle integrity and contaminant measurements.
The workflow begins with virus-containing material produced by host cells, followed by clarification to reduce cellular debris. Selective concentration and purification then use filtration, centrifugation, chromatography, or combinations of these approaches. The resulting preparation is assessed for particle integrity, potency, and contaminant levels, which helps determine whether it is appropriate for research or further manufacturing.
Particle integrity, potency, and contaminant levels provide complementary information about preparation quality. Integrity indicates whether the particles remain structurally acceptable, potency addresses the relevant biological activity, and contaminant measurements show the remaining burden of unwanted material. Considering these measurements together supports decisions about use in controlled research, functional testing, or additional production.
Purified preparations support several research and development activities, including gene-delivery studies, vaccine development, and functional assays. Removing unwanted material and evaluating potency or integrity makes the preparation more suitable for experiments in which viral particles must produce a defined biological effect. The same quality considerations also matter when material is intended for further manufacturing.
Purification contributes to quality control by reducing unwanted components and providing measurable evidence about the final preparation. Researchers can compare particle integrity, biological potency, and contaminant levels with the needs of a specific study or production stage. This information helps distinguish material suitable for research from material requiring additional purification before further manufacturing.